NASDAQ:PBYI Puma Biotechnology (PBYI) Stock Price, News & Analysis $2.85 +0.01 (+0.35%) (As of 10/31/2024 ET) Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends About Puma Biotechnology Stock (NASDAQ:PBYI) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Puma Biotechnology alerts:Sign Up Key Stats Today's Range$2.77▼$2.9350-Day Range$2.25▼$2.9552-Week Range$2.22▼$7.73Volume178,695 shsAverage Volume452,408 shsMarket Capitalization$139.79 millionP/E Ratio15.00Dividend YieldN/APrice Target$7.00Consensus RatingBuy Company OverviewPuma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company offers NERLYNX, an oral version of neratinib that is used to treat adult patients with early stage HER2-overexpressed/amplified breast cancer; and advanced or metastatic HER2-positive breast cancer when combined with capecitabine. It also develops alisertib, a small molecule inhibitor of aurora kinase A for the treatment of hormone receptor positive breast cancer, triple negative breast cancer, small cell lung cancer, and head and neck cancer. The company sells its products through specialty pharmacy and distributor networks. It has license agreements with Pfizer Inc. for the development, manufacture, and commercialization of neratinib (oral), neratinib (intravenous), PB357, and related compounds; and Takeda Pharmaceutical Company Limited for the research, development, and commercialization of alisertib, as well as sub-license agreements with Specialised Therapeutics Asia Pte Ltd., Medison Pharma Ltd., Pint Pharma International SA, Knight Therapeutics, Inc., Pierre Fabre Medicament SAS, and Bixink Therapeutics Co., Ltd. The company was founded in 2010 and is headquartered in Los Angeles, California.Read More… Banking failure dead ahead (Ad)If you missed it, my emergency election broadcast is now available - but will be removed soonClick here to watch it now. Puma Biotechnology Stock Analysis - MarketRank™See Top Rated MarketRank™ Stocks61st Percentile Overall ScorePBYI MarketRank™: Puma Biotechnology scored higher than 61% of companies evaluated by MarketBeat, and ranked 475th out of 993 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingBuy Consensus RatingPuma Biotechnology has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Amount of Analyst CoveragePuma Biotechnology has only been the subject of 1 research reports in the past 90 days.Read more about Puma Biotechnology's stock forecast and price target. Earnings and Valuation1.3 / 5Proj. Earnings Growth-4.00% Earnings GrowthEarnings for Puma Biotechnology are expected to decrease by -4.00% in the coming year, from $0.25 to $0.24 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Puma Biotechnology is 15.00, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 133.66.Price to Earnings Ratio vs. SectorThe P/E ratio of Puma Biotechnology is 15.00, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 131.59.Price to Book Value per Share RatioPuma Biotechnology has a P/B Ratio of 2.54. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Puma Biotechnology's valuation and earnings. Short Interest0.0 / 5Short Interest LevelBearish Percentage of Shares Shorted10.30% of the float of Puma Biotechnology has been sold short.Short Interest Ratio / Days to CoverPuma Biotechnology has a short interest ratio ("days to cover") of 11.2, which indicates bearish sentiment.Change versus previous monthShort interest in Puma Biotechnology has recently increased by 6.16%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldPuma Biotechnology does not currently pay a dividend.Dividend GrowthPuma Biotechnology does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted10.30% of the float of Puma Biotechnology has been sold short.Short Interest Ratio / Days to CoverPuma Biotechnology has a short interest ratio ("days to cover") of 11.2, which indicates bearish sentiment.Change versus previous monthShort interest in Puma Biotechnology has recently increased by 6.16%, indicating that investor sentiment is decreasing significantly. News and Social Media2.5 / 5News Sentiment0.57 News SentimentPuma Biotechnology has a news sentiment score of 0.57. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.68 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Puma Biotechnology this week, compared to 2 articles on an average week.MarketBeat Follows4 people have added Puma Biotechnology to their MarketBeat watchlist in the last 30 days. Company Ownership4.2 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Puma Biotechnology insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $81,519.00 in company stock.Percentage Held by Insiders23.70% of the stock of Puma Biotechnology is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions61.29% of the stock of Puma Biotechnology is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Puma Biotechnology's insider trading history. Receive PBYI Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Puma Biotechnology and its competitors with MarketBeat's FREE daily newsletter. Email Address PBYI Stock News HeadlinesSHAREHOLDER ALERT: Kaskela Law LLC Announces Investigation of Puma Biotechnology, Inc. (NASDAQ: PBYI) and Encourages Investors to Contact the FirmOctober 29 at 8:30 AM | globenewswire.comPuma Biotechnology to Host Conference Call to Discuss Third Quarter Financial ResultsOctober 25, 2024 | finance.yahoo.comThe real reason Elon is fully endorsing TrumpElon Musk is one of mankind’s greatest innovators. But for all his visionary prowess and contributions to humanity, there is a war being waged on Elon Musk. This war has nothing to do with X, Elon’s stance on immigration or his support for Donald Trump. October 31, 2024 | Porter & Company (Ad)Zacks Research Has Bullish Estimate for PBYI FY2026 EarningsOctober 23, 2024 | americanbankingnews.comPuma Biotechnology IncOctober 18, 2024 | money.usnews.comPuma Biotechnology Inc (PBYI)September 18, 2024 | investing.comPuma Biotechnology to Present at the H.C. Wainwright 26th Annual Global Investment ConferenceSeptember 4, 2024 | finance.yahoo.comThe Future of Medicine: Key Biotech Stocks to WatchAugust 21, 2024 | theglobeandmail.comSee More Headlines PBYI Stock Analysis - Frequently Asked Questions How have PBYI shares performed this year? Puma Biotechnology's stock was trading at $4.33 at the beginning of the year. Since then, PBYI shares have decreased by 34.2% and is now trading at $2.85. View the best growth stocks for 2024 here. How were Puma Biotechnology's earnings last quarter? Puma Biotechnology, Inc. (NASDAQ:PBYI) released its quarterly earnings data on Thursday, August, 1st. The biopharmaceutical company reported ($0.09) earnings per share for the quarter, beating the consensus estimate of ($0.10) by $0.01. The biopharmaceutical company had revenue of $47.10 million for the quarter, compared to the consensus estimate of $43.99 million. Puma Biotechnology had a trailing twelve-month return on equity of 18.36% and a net margin of 4.01%. Who are Puma Biotechnology's major shareholders? Top institutional shareholders of Puma Biotechnology include Patriot Financial Group Insurance Agency LLC (0.04%) and SG Americas Securities LLC (0.03%). Insiders that own company stock include Alan H Auerbach, Maximo F Nougues, Jeffrey Jerome Ludwig, Alvin F Wong, Douglas M Hunt, Michael Patrick Miller and Troy Edward Wilson. View institutional ownership trends. How do I buy shares of Puma Biotechnology? Shares of PBYI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Puma Biotechnology own? Based on aggregate information from My MarketBeat watchlists, some other companies that Puma Biotechnology investors own include Incyte (INCY), BioMarin Pharmaceutical (BMRN), (MDVN) (MDVN), First Solar (FSLR), Humana (HUM), American Water Works (AWK) and NVIDIA (NVDA). Company Calendar Last Earnings8/01/2024Today10/31/2024Next Earnings (Confirmed)11/07/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:PBYI CUSIPN/A CIK1401667 Webwww.pumabiotechnology.com Phone(424) 248-6500Fax424-248-6501Employees185Year FoundedN/APrice Target and Rating Average Stock Price Target$7.00 High Stock Price Target$7.00 Low Stock Price Target$7.00 Potential Upside/Downside+145.6%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)$0.19 Trailing P/E Ratio15.00 Forward P/E Ratio11.40 P/E GrowthN/ANet Income$21.59 million Net Margins4.01% Pretax Margin4.59% Return on Equity18.36% Return on Assets4.13% Debt Debt-to-Equity Ratio0.90 Current Ratio1.32 Quick Ratio1.23 Sales & Book Value Annual Sales$235.60 million Price / Sales0.59 Cash Flow$0.67 per share Price / Cash Flow4.24 Book Value$1.12 per share Price / Book2.54Miscellaneous Outstanding Shares49,050,000Free Float37,423,000Market Cap$139.79 million OptionableOptionable Beta1.09 Social Links A Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for November 2024. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.Get This Free Report This page (NASDAQ:PBYI) was last updated on 10/31/2024 by MarketBeat.com Staff From Our PartnersTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | Sponsoredtop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligen...Traders Agency | SponsoredNvidia is Pivoting to Solve Big Tech’s $1 Trillion ProblemTaiwan Semiconductor, a partner of Nvidia’s for more than two decades, has seen its shares explode as much as ...Weiss Ratings | Sponsored“Buffett Indicator” Predicts 62% Stock Market CrashThe last time the "Buffett Indicator" flashed this red was in 2000 - right before the market crashed 50%.Behind the Markets | SponsoredTrump or Kamala? It may come down to this strange twist…Could this be the key to America's second coming? A strange resurrection born in the hollers of Appalachia? ...Porter & Company | Sponsored625,000% GainThe recent pullback in the crypto markets has left many investors in full-on panic mode, convinced the bull ru...Crypto Swap Profits | SponsoredGold at $2,600... But This Stock Gives You More for Under $20Gold just soared over $2,600 an ounce. But what if I told you there's a way to get exposure to MORE than an...Monument Traders Alliance | SponsoredCNBC’s ‘Prophet’ issues urgent Fed warning"How I 6X-ed my wife's 401K in 1 year" At the peak of the dot-com boom, a former hedge fund manager put all...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Puma Biotechnology, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Puma Biotechnology With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.